Chronic prostatic inflammation (CPI) can cause symptomatic or complicated benign prostatic hyperplasia (BPH). Based on available data, Capistan, a hexane extract of Serenoa repens (HESr), has anti-inflammatory properties.
The aim of the present study was to provide a new insight into the anti-inflammatory effects of HESr by investigating the effect on CPI biomarkers in men with lower urinary tract symptoms (LUTS) due to BPH, while using non-invasive methods and exploring the association between the level of biomarkers and clinical symptoms.